Why the study?
Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?
Does apixaban reduce stroke or systemic embolism in patients with subclinical atrial fibrillation?
In patients with subclinical atrial fibrillation, apixaban reduces the risk of stroke or systemic embolism compared to aspirin, but increases the risk of major bleeding.
Apixaban reduces stroke or embolism versus aspirin in subclinical AF but raises major bleeding; extends randomized anticoagulation evidence to device-detected cases.
Among patients with subclinical atrial fibrillation, apixaban resulted in a lower risk of stroke or systemic embolism than aspirin but a higher risk of major bleeding. (Funded by the Canadian Institutes of Health Research and others; ARTESIA ClinicalTrials.gov number, NCT01938248.).
No takes yet. Share an insight, caveat, or question.
Healey et al. (2023) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: